The Comparative Genomics and Network Analysis of eNOS by Using Different Bioinformatics Approaches

Q4 Pharmacology, Toxicology and Pharmaceutics
J. Parkash, Arpita Banerjee, Randeep Singh, Nymphaea Arora, Tania Arora, Vikash Prashar, P. Godara, Arti Sharma, H. Changotra
{"title":"The Comparative Genomics and Network Analysis of eNOS by Using Different Bioinformatics Approaches","authors":"J. Parkash, Arpita Banerjee, Randeep Singh, Nymphaea Arora, Tania Arora, Vikash Prashar, P. Godara, Arti Sharma, H. Changotra","doi":"10.2174/1875692120666230126110252","DOIUrl":null,"url":null,"abstract":"\n\nNitric oxide synthase (NOS) is an enzyme that catalyzes the synthesis of nitric oxide (NO) from L-arginine. It has three isoforms: (1) neuronal NOS (nNOS or NOS1), which participates in neural transmission; (2) inducible NOS (iNOS or NOS2), which produces NO in macrophages; and (3) endothelial NOS (eNOS or NOS3) that regulates blood pressure. The eNOS is mainly expressed in blood vessels and is a crucial regulator of endothelial homeostasis.\n\n\n\nThe present study aimed to unravel the role of eNOS in different signaling pathways and its involvement as a therapeutic target in various neurodegenerative disorders.\n\n\n\nThis study used various in silico methods for comprehensive genomic analysis of eNOS in 16 organisms from 7 different phyla. Prediction of conserved domains and evolutionary relationship for eNOS among 16 organisms was made. Various physical and chemical parameters, signal peptides, and transmembrane regions that helped understand its functional relevance were also studied.\n\n\n\nThree transcription factor binding sites (TFBS), i.e., CP2, AR, and LDSPOLYA, were identified in human eNOS, while ATF1, T3R, and STAT1 were predicted in mouse eNOS. Transcription factors were identified for each regulatory region in human as well as mouse eNOS. eNOS protein was predicted to harbor 14 different post-translational modification (PTM) sites, most of which have phosphorylation (serine followed by threonine and tyrosine phosphorylation) followed by sumoylation and palmitoylation among all the organisms used in the current study. However, human eNOS has a relatively lower number of PTM sites for tyrosine phosphorylation.\n\n\n\nStructures of eNOS isoform, consistent with available biochemical and structural data, provide substantial insight into the NOS conformational changes, which give in-depth knowledge of the mechanism of eNOS, and will be helpful for better understanding the role of eNOS in pathophysiology.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"2001 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692120666230126110252","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Nitric oxide synthase (NOS) is an enzyme that catalyzes the synthesis of nitric oxide (NO) from L-arginine. It has three isoforms: (1) neuronal NOS (nNOS or NOS1), which participates in neural transmission; (2) inducible NOS (iNOS or NOS2), which produces NO in macrophages; and (3) endothelial NOS (eNOS or NOS3) that regulates blood pressure. The eNOS is mainly expressed in blood vessels and is a crucial regulator of endothelial homeostasis. The present study aimed to unravel the role of eNOS in different signaling pathways and its involvement as a therapeutic target in various neurodegenerative disorders. This study used various in silico methods for comprehensive genomic analysis of eNOS in 16 organisms from 7 different phyla. Prediction of conserved domains and evolutionary relationship for eNOS among 16 organisms was made. Various physical and chemical parameters, signal peptides, and transmembrane regions that helped understand its functional relevance were also studied. Three transcription factor binding sites (TFBS), i.e., CP2, AR, and LDSPOLYA, were identified in human eNOS, while ATF1, T3R, and STAT1 were predicted in mouse eNOS. Transcription factors were identified for each regulatory region in human as well as mouse eNOS. eNOS protein was predicted to harbor 14 different post-translational modification (PTM) sites, most of which have phosphorylation (serine followed by threonine and tyrosine phosphorylation) followed by sumoylation and palmitoylation among all the organisms used in the current study. However, human eNOS has a relatively lower number of PTM sites for tyrosine phosphorylation. Structures of eNOS isoform, consistent with available biochemical and structural data, provide substantial insight into the NOS conformational changes, which give in-depth knowledge of the mechanism of eNOS, and will be helpful for better understanding the role of eNOS in pathophysiology.
利用不同生物信息学方法的eNOS比较基因组学和网络分析
一氧化氮合成酶(NOS)是一种催化l -精氨酸合成一氧化氮(NO)的酶。它有三种亚型:(1)神经元NOS (nNOS或NOS1),参与神经传递;(2)诱导NOS (iNOS或NOS2),在巨噬细胞中产生NO;(3)调节血压的内皮细胞NOS (eNOS或NOS3)。eNOS主要在血管中表达,是内皮稳态的重要调节因子。本研究旨在揭示eNOS在不同信号通路中的作用及其作为各种神经退行性疾病的治疗靶点的参与。本研究采用多种计算机方法对来自7个不同门的16种生物的eNOS进行了全面的基因组分析。预测了16种生物eNOS的保守结构域和进化关系。我们还研究了各种物理和化学参数、信号肽和跨膜区域,以帮助了解其功能相关性。在人eNOS中鉴定到三个转录因子结合位点(TFBS),即CP2、AR和LDSPOLYA,而在小鼠eNOS中预测到ATF1、T3R和STAT1。在人类和小鼠的eNOS中,每个调控区域都鉴定了转录因子。预计eNOS蛋白含有14个不同的翻译后修饰(PTM)位点,在本研究中使用的所有生物中,大多数位点都有磷酸化(丝氨酸磷酸化,苏氨酸磷酸化,酪氨酸磷酸化),然后是sumo酰化和棕榈酰化。然而,人类eNOS中酪氨酸磷酸化的PTM位点数量相对较少。eNOS异构体的结构与现有的生物化学和结构数据一致,为深入了解eNOS的构象变化提供了重要依据,有助于深入了解eNOS的机制,并有助于更好地理解eNOS在病理生理中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Pharmacogenomics and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
0.40
自引率
0.00%
发文量
11
期刊介绍: Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信